First Wave BioPharma, Inc. announced the appointment of Brian Feagan, M.D., Professor of Medicine, Epidemiology and Biostatistics at Western University and Senior Scientific Director, Alimentiv, Inc., to the company's scientific advisory board, effective December 9, 2021. Dr. Feagan will join Anthony Opipari, M.D., Ph.D.; Richard Marlink, M.D.; and Michael Konstan, M.D., on the First Wave BioPharma SAB. The SAB will work with management to guide and support First Wave BioPharma as it continues to advance its pipeline of development- and clinical-stage programs built around its two gut-restricted GI technologies – niclosamide, a small molecule with anti-viral and anti-inflammatory properties, and adrulipase, a recombinant lipase enzyme designed to help with the digestion of fats and other nutrients.